Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 11/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | FNTA | P49354 | 1/20 | 0.52 |
| ▸ | FNTB | P49356 | 1/20 | 0.52 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.52 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6923102 | 0.91 | GRIN2B (0.53) | GRIN2BCYP2D6CYP2C9CYP3A4SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL6926446 | 0.90 | GRIN2B (0.53) | GRIN2BCYP2D6CYP2C9CYP3A4SMN1; SMN2 | |
| SCHEMBL6928071 | 0.88 | FNTA (0.55) | GRIN2BCYP2D6CYP2C9CYP3A4SMN1; SMN2 | |
| SCHEMBL6929325 | 0.87 | SMN1; SMN2 (0.53) | GRIN2BCYP2D6CYP2C9CYP3A4SMN1; SMN2 | |
| SCHEMBL6924453 | 0.80 | GRIN2B (0.54) | GRIN2BCYP2D6CYP2C9CYP3A4SMN1; SMN2 | |
| SCHEMBL28690825 | 0.78 | SMN1; SMN2 (0.58) | GRIN2BCYP2D6CYP2C9CYP3A4SMN1; SMN2 | |
| SCHEMBL458805 | 0.78 | SMN1; SMN2 (0.72) | GRIN2BCYP2D6CYP2C9CYP3A4SMN1; SMN2 | |
| SCHEMBL29671511 | 0.76 | SMN1; SMN2 (0.65) | GRIN2BCYP2D6CYP2C9CYP3A4SMN1; SMN2 | |
| SCHEMBL458148 | 0.75 | SMN1; SMN2 (0.68) | GRIN2BCYP2D6CYP2C9CYP3A4SMN1; SMN2 | |
| SCHEMBL15140566 | 0.75 | SMN1; SMN2 (0.72) | GRIN2BCYP2D6CYP2C9CYP3A4SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1158277-C | Farnesyl transferase inhibitor with piperidine structure and preparation method thereof | LG��ѧ��ʽ���� | 2004-07-21 | — | — | CN | disclosed |
| EP-1045846-B1 | IMIDAZOLE DERIVATIVES HAVING AN INHIBITORY ACTIVITY FOR FARNESYL TRANSFERASE AND PROCESS FOR PREPARATION THEREOF | LG CHEMICAL LTD (KR) | 2003-05-02 | — | — | EP | disclosed |
| US-6518429-B2 | Anticancer agents, treating restenosis, atherosclerosis and hepatitis virus | LG CHEMICAL, LTD. (KR) | 2003-02-11 | — | — | US | disclosed |
| EP-1058683-B1 | FARNESYL TRANSFERASE INHIBITORS HAVING A PIPERIDINE STRUCTURE AND PROCESS FOR PREPARATION THEREOF | LG CHEMICAL LTD (KR) | 2002-12-04 | — | — | EP | disclosed |
| US-6472526-B1 | SHOWS AN INHIBITORY ACTIVITY AGAINST FARNESYL TRANSFERASE OR PHARMACEUTICALLY ACCEPTABLE SALTS OR ISOMERS THEREOF, IN PHARMACEUTICAL COMPOSITION AND INTERMEDIATES | LG CHEMICAL LTD. (KR) | 2002-10-29 | — | — | US | disclosed |
| US-20020137769-A1 | Imidazole derivatives having an inhibitory activity for farnesyl transferase and process for preparation thereof | LG CHEMICAL LTD. | 2002-09-26 | — | — | US | disclosed |
| US-6436960-B1 | TREATING CANCER, RESTENOSIS, ATHEROSCLEROSIS AND INFECTIONS FROM HEPATITIS DELTA AND RELATED VIRUSES. | LG CHEMICAL LTD. (KR) | 2002-08-20 | — | — | US | disclosed |
| US-6384061-B1 | HYDANTOIN COMPOUNDS REPRESENTED BY FORMULA (I) WHICH SHOWS AN INHIBITORY ACTIVITY AGAINST FARNESYL TRANSFERASE, AND THUS CAN BE USED AS AN ANTI-CANCER AGENT, OR PHARMACEUTICALLY ACCEPTABLE SALTS | LG CHEMICAL LTD. (KR) | 2002-05-07 | — | — | US | disclosed |
| US-6268363-B1 | ANTITUMOR | LG CHEMICAL LTD. (KR) | 2001-07-31 | — | — | US | disclosed |
| CN-1289331-A | Farnesyl transferase inhibitors having a piperidine structure and process for preparation thereof | LG CHEMICAL LTD (KR) | 2001-03-28 | — | — | CN | disclosed |
| EP-1045846-A1 | IMIDAZOLE DERIVATIVES HAVING AN INHIBITORY ACTIVITY FOR FARNESYL TRANSFERASE AND PROCESS FOR PREPARATION THEREOF | LG CHEMICAL LIMITED (KR) | 2000-10-25 | — | — | EP | disclosed |
| EP-1000036-A1 | HYDANTOIN DERIVATIVES HAVING AN INHIBITORY ACTIVITY FOR FARNESYL TRANSFERASE | LG CHEMICAL LIMITED (KR) | 2000-05-17 | — | — | EP | disclosed |
| WO-1999028315-A1 | IMIDAZOLE DERIVATIVES HAVING AN INHIBITORY ACTIVITY FOR FARNESYL TRANSFERASE AND PROCESS FOR PREPARATION THEREOF | LG CHEMICAL LTD. (KR) | 1999-06-10 | — | — | WO | disclosed |
| WO-1999005117-A1 | HYDANTOIN DERIVATIVES HAVING AN INHIBITORY ACTIVITY FOR FARNESYL TRANSFERASE | LG CHEMICAL LTD. (KR) | 1999-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137769-A1 | Imidazole derivatives having an inhibitory activity for farnesyl transferase and process for preparation thereof | FNTA, FNTB, FDPS | GRIN2B 4822/4885CYP2D6 528/4885CYP2C9 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.